• Reliq Health Technologies has signed contracts with three physician practices in Texas
  • Reliq will provide its iUGO Care platform to their chronic disease patients
  • The average revenue from these contracts will be US$65 per patient per month
  • Reliq Health Technologies specializes in developing Software-as-a-Service solutions for remote patient monitoring, telemedicine, and care collaboration
  • iUGO Care provides real-time access to remote patient monitoring data
  • Reliq Health Technologies Inc. (RHT) opened trading at C$0.445 per share

Reliq Health Technologies (RHT) has signed contracts with three physician practices to provide its iUGO Care platform to their patients.

“We are very pleased to be adding three new US physician practices to our iUGO Care platform,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc.

“The average revenue from these contracts will be US$65 per patient per month. All three of these new clients will go live this month. Onboarding with all clients is proceeding per the guidance we have provided for 2021, and we remain on track to exit December 2021 at a run rate of $2,000,000 per month in revenue. We expect to work through our backlog of over 200,000 patients in the next 18-24 months as the healthcare sector continues its recovery from the global pandemic.”

Reliq Health Technologies is a rapidly growing global telemedicine that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq’s powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high-quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery.

iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits.

Reliq Health Technologies Inc. (RHT) opened trading at C$0.445 per share.

More From The Market Online

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.

WELL Health and Microsoft to future-proof North American healthcare

WELL Health Technologies (TSX:WELL) and Microsoft (NDAQ:MSFT) sign a five-year deal to expedite healthcare's transition into the digital age.